trending Market Intelligence /marketintelligence/en/news-insights/trending/ixqzlesyfb-4jtesytqzgw2 content esgSubNav
In This List

Achillion Pharmaceuticals appoints former uniQure exec as COO

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022

Blog

Insight Weekly: Reviving nuclear power; 2023 outlook for US financials; PE funds fuel EV sector


Achillion Pharmaceuticals appoints former uniQure exec as COO

Achillion Pharmaceuticals Inc. named Paul Firuta to the positions of executive vice president and COO, effective Sept. 10.

Firuta most recently served as the chief commercial officer of uniQure NV, an Amsterdam-based gene-editing company.

Prior to joining uniQure, Firuta was the president of U.S. commercial operations in Bedminster, N.J.-based NPS Pharmaceuticals Inc., a biopharmaceutical company that develops treatments for gastrointestinal and endocrine disorders.

New Haven, Conn.-based Achillion Pharmaceuticals is focused on developing its oral factor D inhibitors to treat rare diseases with no or inadequate approved therapies.